<DOC>
	<DOC>NCT02138500</DOC>
	<brief_summary>This study will see how PF-06372865, an experimental drug distributes in the brain after one dose of PF-06372865 is administered orally to healthy volunteer subjects. The study will also evaluate the safety and tolerability of PF-06372865in these subjects and will measure the level of PF-06372865 in the blood.</brief_summary>
	<brief_title>A Study to Examine the Distribution of PF-06372865 in the Brain of Healthy Volunteers Using Positron Emission Tomography and a Radioactive Tracer Following Oral Administration of One Dose of PF-06372865</brief_title>
	<detailed_description />
	<criteria>Healthy male subjects and female subjects of nonchildbearing potential between the ages of 18 and 55 years, inclusive. Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight &gt;50 kg (110 lbs). Subjects who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, and other study procedures. Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing). Any condition possibly affecting drug absorption (eg, gastrectomy). Known or suspected sensitivity to flumazenil and other benzodiazepines.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>PF-06372865</keyword>
	<keyword>phase 1</keyword>
	<keyword>open-label</keyword>
	<keyword>GABA-A receptor occupancy</keyword>
	<keyword>positron emission tomography</keyword>
	<keyword>healthy subjects</keyword>
</DOC>